靶向中期因子的反义寡核苷酸可抑制体内血管生成。
Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.
作者信息
Dai Li-Cheng, Wang Xiang, Yao Xing, Lu Yong-Liang, Ping Jin-Liang, He Jian-Fang
机构信息
Huzhou Key Laboratory of Molecular Medicine, Huzhou Central Hospital, Huzhou 313000, Zhejiang Province, China.
出版信息
World J Gastroenterol. 2007 Feb 28;13(8):1208-13. doi: 10.3748/wjg.v13.i8.1208.
Abstract
AIM
To evaluate the effect of antisense oligonucleotide targeting midkine (MK-AS) on angiogenesis in chick chorioallantoic membrane (CAM) and in situ human hepatocellular carcinoma (HCC).
METHODS
An in situ human hepatocellular carcinoma (HCC) model and CAM assay were used in this experiment. The effect of MK-AS on angiogenesis was evaluated by cell proliferation assay and hematoxylin-eosin (HE) staining.
RESULTS
MK-AS significantly inhibited human umbilical vein endothelial cells (HUVEC) and in situ human HCC growth. At the same time, MK-AS suppressed the angiogenesis both in human hepatocellular carcinoma cell line (HEPG2)-induced CAM and in situ human HCC tissues.
CONCLUSION
MK-AS is an effective antiangiogenesis agent in vivo.
摘要
目的
评估靶向中期因子的反义寡核苷酸（MK-AS）对鸡胚绒毛尿囊膜（CAM）血管生成及人原位肝细胞癌（HCC）的影响。
方法
本实验采用人原位肝细胞癌模型及CAM试验。通过细胞增殖试验和苏木精-伊红（HE）染色评估MK-AS对血管生成的影响。
结果
MK-AS显著抑制人脐静脉内皮细胞（HUVEC）及人原位肝癌生长。同时，MK-AS抑制人肝癌细胞系（HEPG2）诱导的CAM及人原位肝癌组织中的血管生成。
结论
MK-AS在体内是一种有效的抗血管生成剂。
相似文献
1
Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.靶向中期因子的反义寡核苷酸可抑制体内血管生成。
World J Gastroenterol. 2007 Feb 28;13(8):1208-13. doi: 10.3748/wjg.v13.i8.1208.
2
Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.联合化疗药物与中期因子反义寡核苷酸对肝细胞癌的增强治疗效果
World J Gastroenterol. 2007 Apr 7;13(13):1989-94. doi: 10.3748/wjg.v13.i13.1989.
3
Antisense oligonucleotides targeting midkine induced apoptosis and increased chemosensitivity in hepatocellular carcinoma cells.靶向中期因子的反义寡核苷酸可诱导肝癌细胞凋亡并增强其化学敏感性。
Acta Pharmacol Sin. 2006 Dec;27(12):1630-6. doi: 10.1111/j.1745-7254.2006.00459.x.
4
Antisense oligonucleotides targeting midkine inhibit tumor growth in an in situ human hepatocellular carcinoma model.靶向中期因子的反义寡核苷酸在原位人肝细胞癌模型中抑制肿瘤生长。
Acta Pharmacol Sin. 2007 Mar;28(3):453-8. doi: 10.1111/j.1745-7254.2007.00532.x.
5
In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-antisense oligonucleotide-loaded nanoparticles.负载中期因子反义寡核苷酸的纳米颗粒对肝癌生长的体内外抑制作用
World J Gastroenterol. 2009 Apr 28;15(16):1966-72. doi: 10.3748/wjg.15.1966.
6
Total alkaloids of Rubus alceifolius Poir shows anti-angiogenic activity in vivo and in vitro.悬钩子总生物碱在体内和体外均表现出抗血管生成活性。
Integr Cancer Ther. 2014 Nov;13(6):520-8. doi: 10.1177/1534735414547109. Epub 2014 Aug 22.
7
Large scale preparation of midkine antisense oligonucleotides nanoliposomes by a cross-flow injection technique combined with ultrafiltration and high-pressure extrusion procedures.采用流加注射技术结合超滤和高压挤出技术大规模制备中期因子反义寡核苷酸纳米脂质体。
Int J Pharm. 2013 Jan 30;441(1-2):712-20. doi: 10.1016/j.ijpharm.2012.10.023. Epub 2012 Nov 6.
8
In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin.长春碱和雷帕霉素对人肝细胞癌相关血管生成的体内抑制作用
Histol Histopathol. 2007 Mar;22(3):285-9. doi: 10.14670/HH-22.285.
9
New Natural Pigment Fraction Isolated from Saw Palmetto: Potential for Adjuvant Therapy of Hepatocellular Carcinoma.从锯叶棕中分离出的新型天然色素组分：肝细胞癌辅助治疗的潜力。
Int J Mol Sci. 2016 Aug 5;17(8):1277. doi: 10.3390/ijms17081277.
10
The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma.鸡胚绒毛尿囊膜（CAM）检测作为肝细胞癌的高效异种移植模型
J Vis Exp. 2015 Oct 9(104):52411. doi: 10.3791/52411.
引用本文的文献
1
Significance of Midkine Signaling in Women's Cancers: Novel Biomarker and Therapeutic Target.中期因子信号通路在女性癌症中的意义：新型生物标志物与治疗靶点
Int J Mol Sci. 2025 May 17;26(10):4809. doi: 10.3390/ijms26104809.
2
Midkine-A novel player in cardiovascular diseases.中期因子——心血管疾病中的新角色。
Front Cardiovasc Med. 2022 Sep 20;9:1003104. doi: 10.3389/fcvm.2022.1003104. eCollection 2022.
3
Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury.中期因子：针对围产期脑损伤的一种有前景的神经营养疗法的相关要素（何人、何事、何地及何时）
Front Neurol. 2020 Oct 22;11:568814. doi: 10.3389/fneur.2020.568814. eCollection 2020.
4
Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.中期因子 (MDK) 生长因子：癌症进展中的关键角色和有前途的治疗靶点。
Oncogene. 2020 Mar;39(10):2040-2054. doi: 10.1038/s41388-019-1124-8. Epub 2019 Dec 4.
5
Inhibitory effect of midkine-binding peptide on tumor proliferation and migration.中期因子结合肽对肿瘤增殖和迁移的抑制作用
Int J Clin Exp Pathol. 2015 May 1;8(5):5387-94. eCollection 2015.
6
Therapeutic potential of midkine in cardiovascular disease.中期因子在心血管疾病中的治疗潜力
Br J Pharmacol. 2014 Feb;171(4):936-44. doi: 10.1111/bph.12537.
7
Neuroglycan C, a brain-specific chondroitin sulfate proteoglycan, interacts with pleiotrophin, a heparin-binding growth factor.神经糖蛋白 C，一种脑特异性硫酸软骨素蛋白聚糖，与肝素结合生长因子多效蛋白相互作用。
Neurochem Res. 2010 Aug;35(8):1131-7. doi: 10.1007/s11064-010-0164-9. Epub 2010 Apr 6.
8
Midkine translocated to nucleoli and involved in carcinogenesis.中期因子易位至核仁并参与肿瘤发生。
World J Gastroenterol. 2009 Jan 28;15(4):412-6. doi: 10.3748/wjg.15.412.
本文引用的文献
1
Antisense oligonucleotides targeting midkine inhibit tumor growth in an in situ human hepatocellular carcinoma model.靶向中期因子的反义寡核苷酸在原位人肝细胞癌模型中抑制肿瘤生长。
Acta Pharmacol Sin. 2007 Mar;28(3):453-8. doi: 10.1111/j.1745-7254.2007.00532.x.
2
Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia.儿童B前体急性淋巴细胞白血病中中期因子基因表达增加。
Leuk Res. 2007 Aug;31(8):1045-51. doi: 10.1016/j.leukres.2006.12.008. Epub 2007 Jan 30.
3
Antisense oligonucleotides targeting midkine induced apoptosis and increased chemosensitivity in hepatocellular carcinoma cells.靶向中期因子的反义寡核苷酸可诱导肝癌细胞凋亡并增强其化学敏感性。
Acta Pharmacol Sin. 2006 Dec;27(12):1630-6. doi: 10.1111/j.1745-7254.2006.00459.x.
4
Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts.针对中期因子的小干扰RNA与紫杉醇联合应用对人前列腺癌异种移植瘤生长的抗肿瘤作用
Cancer. 2006 Aug 15;107(4):864-73. doi: 10.1002/cncr.22068.
5
Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder.血清血管生成活性在膀胱移行细胞癌患者中的临床相关性。
J Cell Mol Med. 2005 Jul-Sep;9(3):655-61. doi: 10.1111/j.1582-4934.2005.tb00495.x.
6
Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model.在原位人肝细胞癌模型中，用靶向人端粒酶逆转录酶（Cantide）的反义寡核苷酸抑制肿瘤生长和转移。
Acta Pharmacol Sin. 2005 Jun;26(6):762-8. doi: 10.1111/j.1745-7254.2005.00762.x.
7
Midkine induced growth of ameloblastoma through MAPK and Akt pathways.中期因子通过丝裂原活化蛋白激酶（MAPK）和蛋白激酶B（Akt）信号通路诱导成釉细胞瘤生长。
Oral Oncol. 2004 Mar;40(3):274-80. doi: 10.1016/j.oraloncology.2003.08.011.
8
Angiogenic and angiostatic factors in the molecular control of angiogenesis.血管生成分子调控中的血管生成和血管生成抑制因子
Q J Nucl Med. 2003 Sep;47(3):149-61.
9
Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.中期因子与间变性淋巴瘤激酶（ALK）结合，并作为不同细胞类型的生长因子发挥作用。
J Biol Chem. 2002 Sep 27;277(39):35990-8. doi: 10.1074/jbc.M205749200. Epub 2002 Jul 16.
10
Angiogenesis in bladder cancer--prognostic marker and target for future therapy.膀胱癌中的血管生成——预后标志物及未来治疗靶点
Surg Oncol. 2002 Jun;11(1-2):85-100. doi: 10.1016/s0960-7404(02)00013-0.
Zotero 插件